查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587471

液态切片市场规模、份额、趋势分析报告：按循环生物标记、按应用、按地区、细分市场预测，2025-2030 年

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

液态切片市场成长和趋势：

预计2030年全球液态切片市场规模将达19亿美元，2025年至2030年复合年增长率预计为8.5%。

这种增长的推动因素是人们对无创技术的日益偏好、早期诊断和治疗意识的提高以及乳癌盛行率的上升。例如，根据世界卫生组织的数据，2020年全球有68.5万名女性死于乳癌，230万名女性被诊断出罹患乳癌。液态切片被认为是乳癌早期检测的突破性技术，这正在推动乳癌的采用并刺激成长。

随着乳癌盛行率的不断增加，迫切需要提供适当的诊断工具来早期发现和早期治疗癌症。为了满足日益增长的需求，诊断领域的研究和开发变得更加活跃。例如，2022年6月，BioFluidica研究结果显示，HER2阳性乳癌患者在接受量身定制的HER2定向治疗时成功率有所提高。由于相关领域的进步，液态切片的临床意义越来越为人所知。需要进一步的介入临床试验和创建适当结合循环生物标记的演算法，以使这些技术广泛应用。

由于循环生物标记持续研究的技术突破，已经开发出用于识别非骨髓恶性肿瘤的侵入性较小的技术。与传统的肿瘤切片检查相比，液态切片被认为是即时患者监测的有前途的选择。例如，2022 年 4 月，Epic Sc​​iences, Inc. 在其 CLIA 实验室产品组合中添加了 DefineMBC，这是一种基于液态切片技术的血液检测，用于诊断转移性乳癌。

此外，该市场的主要企业都致力于扩大和推出可用于广泛应用的产品。资料，2022年6月，NeoGenomics子公司Inivata Limited推出了RaDaR检测方法，用于分析人类表皮生长因子受体2（HER2）阴性、患有微量残存疾病（MRD）和復发的高风险患者。

液态切片市场报告亮点

  • 循环性肿瘤细胞(CTC) 领域预计在预测期内将以 9.4% 的最快复合年增长率增长。目前正在进行调查以确定 CTC 在早期乳癌中的效用。
  • 由于液态切片在癌症早期检测中的使用不断增加，预计早期检测/筛检领域在预测期内将以 9.7% 的复合年增长率显着增长。
  • 按应用来看，由早期治疗需求驱动的治疗选择细分市场以 2024 年 51.5% 的最大收益占有率引领市场。
  • 在液态切片市场中，北美地区占据最大收益占有率，2024年为44.64%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章液态切片市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 液态切片市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章液态切片市场：循环生物标记的估计和趋势分析

  • 细分仪表板
  • 液态切片市场：循环生物标记的波动分析
  • 循环生物标记对液态切片市场的展望
  • 2018-2030年市场规模、预测及趋势分析
    • 循环性肿瘤细胞(CTC)
    • 循环细胞 - 游离 DNA (Cfdna)
    • 细胞外囊泡 (Evs)
    • 其他循环生物标记

第五章液态切片市场：应用估算与趋势分析

  • 细分仪表板
  • 液态切片市场：应用变化分析
  • 按应用分類的液态切片市场前景
  • 2018-2030年市场规模、预测及趋势分析
    • 早期发现/筛检
    • 诊断
    • 治疗选择
    • 监控

第六章液态切片市场：区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 主要企业市场占有率，2024年
  • 主要企业简介
    • The Menarini Group
    • NeoGenomics Laboratories
    • F. Hoffmann-La Roche Ltd.,
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific, Inc.
    • QIAGEN
    • Biocept, Inc.
    • Sysmex Corporation
    • Fluxion Biosciences, Inc.
    • Epic Sciences, Inc.
Product Code: GVR-4-68039-991-9

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.90 billion in 2030 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

  • The circulating tumor cells (CTCs) segment is anticipated to grow at the fastest CAGR of 9.4% over the forecast period. There has been ongoing research to specify the utility of CTCs in early-stage breast cancer
  • The early detection/screening segment is expected to grow at a significant CAGR of 9.7% during the forecast period, due to the increasing application of the use of liquid biopsy in the early detection of cancer.
  • Based on application, the treatment selection segments led the market with the largest revenue share of 51.5% in 2024, attributed to the need to provide early treatment
  • North America dominated the breast cancer liquid biopsy market with the largest revenue share of 44.64% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Circulating Biomarkers
    • 1.2.2. Application
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Circulating Biomarkers outlook
    • 2.2.2. Application outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Breast Cancer Liquid Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence Of Breast Cancer
      • 3.2.1.2. Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
      • 3.2.1.3. Need To Provide Early Diagnosis And Treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost Associated With Breast Cancer Liquid Biopsy Tests
      • 3.2.2.2. Regulatory & Reimbursement Hurdles
  • 3.3. Breast Cancer Liquid Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
  • 4.3. Breast Cancer Liquid Biopsy Market by Circulating Biomarkers Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Circulating Tumor Cells (Ctcs)
      • 4.4.1.1. Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.2. Circulating Cell - Free Dna (Cfdna)
      • 4.4.2.1. Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.3. Extracellular Vesicles (Evs)
      • 4.4.3.1. Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4.4. Other Circulating Biomarkers
      • 4.4.4.1. Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Breast Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Breast Cancer Liquid Biopsy Market: Application Movement Analysis
  • 5.3. Breast Cancer Liquid Biopsy Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Early Detection/Screening
      • 5.4.1.1. Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Diagnosis
      • 5.4.2.1. Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Treatment Selection
      • 5.4.3.1. Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4.4. Monitoring
      • 5.4.4.1. Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Breast Cancer Liquid Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Key company market share, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. The Menarini Group
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. NeoGenomics Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. F. Hoffmann - La Roche Ltd.,
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Myriad Genetics, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. QIAGEN
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Biocept, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Sysmex Corporation
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Fluxion Biosciences, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Epic Sciences, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 4. Global Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 5. Global Breast Cancer Liquid Biopsy Market, by region, 2018 - 2030 (USD Million)
  • Table 6. North America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 7. North America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 8. U.S. Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 9. U.S. Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 10. Mexico Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 11. Mexico Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 12. Canada Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 13. Canada Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 14. Europe Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 15. Europe Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 16. Europe Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 17. UK Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 18. UK Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 19. Germany Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 20. Germany Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 21. France Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 22. France Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 23. Italy Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 24. Italy Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 25. Spain Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 26. Spain Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 27. Denmark Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 28. Denmark Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 29. Norway Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 30. Norway Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 31. Sweden Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 32. Sweden Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 33. Asia Pacific Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 36. Japan Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 37. Japan Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 38. China Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 39. China Breast Cancer Liquid Biopsy Market, by application 2018 - 2030 (USD Million)
  • Table 40. India Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 41. India Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 42. Australia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 43. Australia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 44. South Korea Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 45. South Korea Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 46. Thailand Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 47. Thailand Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 48. Latin America Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 49. Latin America Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 50. Latin America Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 51. Brazil Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 52. Brazil Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 53. Argentina Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 54. Argentina Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 55. Middle East & Africa Breast Cancer Liquid Biopsy Market, by country, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 58. South Africa Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 59. South Africa Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 60. Saudi Arabia Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 62. UAE Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 63. UAE Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)
  • Table 64. Kuwait Breast Cancer Liquid Biopsy Market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Breast Cancer Liquid Biopsy Market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Breast Cancer Liquid Biopsy Market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Breast Cancer Liquid Biopsy Market, Circulating Biomarkers outlook key takeaways (USD Million)
  • Fig. 12 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers movement analysis (USD Million), 2024 & 2030
  • Fig. 13 Circulating Tumor Cells (Ctcs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Circulating Cell - Free Dna (Cfdna) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Extracellular Vesicles (Evs) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Other Circulating Biomarkers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Early Detection/Screening market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Diagnosis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Treatment Selection market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Monitoring market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Breast Cancer Liquid Biopsy Market: regional key takeaways (USD Million)
  • Fig. 22 Breast Cancer Liquid Biopsy Market: regional outlook, 2023 & 2030, USD Million
  • Fig. 23 North America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Mexico Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Italy Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Denmark Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Sweden Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 South Korea Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Australia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Breast Cancer Liquid Biopsy Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 List of key emerging company's/liquid biopsy disruptors/innovators